Deltex Medical Group plc (LON:DEMG) CEO Ewan Phillips talks to DirectorsTalk about the release of the initial results from the largest ever randomised clinical trial of ODM which showed substantial reductions in post-operative complications. Ewan provides some background to the study, talks about the trial results, tells us what this means for ODM, explains how Deltex is now well positioned to capitalise on the Spanish market and shares his thoughts on 2016 so far.
Deltex Medical Group Plc manufactures and markets haemodynamic monitoring technologies. Deltex Medical’s ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex Medical has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
